Investment
Features
FeesSafety
Academy
More
Pluang+

KLX Energy nears expiration of $125M rights offering at $1.49/share on Sept 23, 2026

Company Fundamentals
18 Sep 2026
PRNewsWire
View Source
Neutral
KLX Energy nears expiration of $125M rights offering at $1.49/share on Sept 23, 2026

KLX Energy Services Holdings is approaching the September 23, 2026 deadline for its $125 million backstopped rights offering, allowing shareholders to buy shares at $1.49 each. Each right lets holders buy 3.885 shares, with ownership limits to prevent exceeding 9.995% of total shares. The rights trade under symbol KLXER on Nasdaq until the deadline, but brokerage deadlines may be earlier. The company may extend or amend the offering and advises shareholders to check broker deadlines and review the official prospectus for details.

KLX Energy Services rights offering is nearing its September 23, 2026 expiration date. For readers following the energy sector, here is Pluang's market snapshot as of Sep 18, 2026 20:21 WIB: Among 34 priced US energy stocks, 12 rose and 22 fell today. Notable prices include LEU at USD 149.05 with a 1-day change of -0.53% and Pluang order activity of 1% Sell / 99% Buy, OXY at USD 59.50 with a 1-day change of +0.35% and Pluang order activity of 46% Sell / 54% Buy, and LNG at USD 269.00 with a 1-day change of -0.31%.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
2 hours ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
3 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
3 hours ago
HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

HYPE token surged 10.5% to $91.20, reaching a new all-time high of $92.56 after Hyperliquid launched manual borrowing of USDC and USDT using HYPE and Bitcoin as collateral. The platform offers a 65% loan-to-value ratio for HYPE, higher than Bitcoin's...

Market News
Bullish
4 hours ago
CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech Vanadium Mining Corp. has engaged Mercator Geological Services to prepare an independent technical report on its Campbell-Crotser fluorspar project in Kentucky, following National Instrument 43-101 standards. The report will detail geology,...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App